Tao Zhang

Tao Zhang

Auto-generated profile, based on publicly available information

Tao Zhang

Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400000, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SQShukui Qin
Shukui Qin
LJLi Jin
Li Jin
HZHaijun Zhong
Haijun Zhong
CJChuan Jin
Chuan Jin
LCLili Chen
Lili Chen
QWQingyu Wang
Qingyu Wang
2566 Background: Microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) in cells render them susceptible to immune checkpoint blockages. This study aimed to evaluate the efficacy and safety of HLX10, a fully humanized monoclonal antibody against PD-1, in patients with unresectable or metastatic MSI-H/dMMR solid tumors who have progressed on or been intolerant to standard therapies. Methods: In this single-arm, open-label, multicenter, phase 2 study (NCT03941574), patients (18≤ age ≤75 years) with histologically/cytologically confirmed unresectable or metastatic MSI-H/dMMR solid tumors were recruited to receive 3 mg/kg HLX10 every two weeks intravenously for up to 2 years until disease progression, unacceptable toxicity, or patient withdrawal. The primary endpoint was objective response rate (ORR) assessed by IRRC (evaluated every 6 weeks for the first 48 weeks and every 12 weeks thereafter) per RECIST v1.1. Secondary endpoints included ORR assessed by investigators, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. All eligible patients who received at least one dose of HLX10 were included in the safety analyses. Results: As of Jan 9, 2021, 108 patients were enrolled and 68 with locally or centrally confirmed MSI-H were included in the main efficacy analysis population. Among the 68 patients, the median follow-up duration was 7.7 (range: 1.1–16.4) months and the median age was 53.0 (range: 23.0–72.0) years. MSI-H tumor types included colorectal cancer (n = 54), endometrial cancer (n = 5), gastric cancer (n = 4), breast cancer (n = 2), small intestine cancer (n = 2) and fallopian tube cancer (n = 1). IRRC and investigator assessed ORR were 38.2% (95% CI: 26.7–50.8%; 2 complete response) and 35.3% (95% CI: 24.1–47.8%) respectively in the main efficacy analysis population. Median DoR, PFS and OS have not been reached. 105 (97.2%) patients experienced treatment-emergent adverse events (TEAEs), most commonly anemia (34.3%), hypoproteinemia (27.8%) and increased aspartate aminotransferase (25.0%). 53 (49.1%) patients had grade 3 or worse TEAEs, most commonly anemia (8.3%), progressive disease (6.5%), increased γ- glutamyltransferase (5.6%) and intestinal obstruction (5.6%). 52 (48.1%) patients had immune-related adverse events (irAEs) while 10 (9.3%) had grade 3 or worse irAEs. 3 (2.8%) deaths (2 PD and 1 intestinal obstruction) that might be related to the study drug were reported. Conclusions: HLX10 provides encouraging antitumor activity with a manageable safety profile in patients with MSI-H/dMMR solid tumors who have progressed on or been intolerant to standard therapies. As an effective tissue-agnostic treatment, HLX10 possesses the potential to improve patients’ clinical outcomes. Clinical trial information: NCT03941574.

23 February 2022 in Future Oncology
Verified
Journal Article
Closed access
LKLingna Kou
Lingna Kou
TZTao Zhang
Tao Zhang
XYXiling Yang
Xiling Yang
SPSiyun Peng
Siyun Peng
YWYifei Wang
Yifei Wang
MLMinmin Li
Minmin Li
Aims: With the use of concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC), survival outcomes are still not optimal. This study was designed to evaluate the efficacy and ...

17 March 2021 in Future Oncology
Verified
Journal Article
Closed access
WWWei Wang
Wei Wang
TZTao Zhang
Tao Zhang
Aim: PD-L1 is an important immune intervention target for lung cancer treatment; however, its clinical significance and biological function in circulating tumor cells (CTCs) of lung cancer need to ...

1 May 2018 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
ZLZhen Li
Zhen Li
MSMin Song
Min Song
ZHZhun He
Zhun He
LZLing Zong
Ling Zong
BJBo Jiang
Bo Jiang
ZHZhiliang Hu
Zhiliang Hu